WELS:XETRA:XETRA-Amundi S&P Global Health Care ESG UCITS ETF DR EUR Acc (EUR)

ETF | Others |

Last Closing

USD 11.116

Change

-0.03 (-0.29)%

Market Cap

USD 0.24B

Volume

7.62K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.32 (-0.62%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.12 (-0.73%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.20 (-0.74%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.11 (-0.38%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.23 (-0.94%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.08 (-0.05%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

-0.48 (-1.10%)

USD 102.57B
8R80:XETRA Amundi Index Solutions - Amund..

-1.36 (-0.96%)

USD 102.14B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.33 (-0.66%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.74 (-0.14%)

USD 80.38B

ETFs Containing WELS:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.21% 57% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.21% 57% F 58% F
Trailing 12 Months  
Capital Gain 9.11% 50% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.11% 50% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.68% 44% F 44% F
Dividend Return 2.68% 44% F 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.11% 84% B 88% B+
Risk Adjusted Return 52.48% 63% D 66% D+
Market Capitalization 0.24B 52% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.